Bacteria That Break Cancer's Walls: Neobe's $6.8M Bet

·
Listen to this article~3 min

Neobe Therapeutics raises $6.8M to engineer bacteria that break down tumor barriers, potentially making untreatable cancers curable. The London-based startup's approach uses harmless bacteria to dissolve the fibrous matrix around tumors, allowing drugs and immune cells to attack.

What if the reason some cancers resist treatment isn't the drug—but the tumor's physical defenses? That's the question driving Neobe Therapeutics, a London-based bio-engineering startup that just raised $6.8 million (€6.1 million) to engineer bacteria that break down those barriers. The seed round was led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect, and Empirical Ventures, plus follow-on from pre-seed investor 2048 Ventures. Total funding now tops $10.5 million (€9.4 million). ### The Problem: A Wall Around the Tumor Immunotherapy has changed cancer treatment, but it doesn't work for everyone. Often, the failure is physical, not biological. A dense, fibrous matrix forms around solid tumors, creating a wall that immune cells and drugs simply can't cross. "Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed," says Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe. ### The Solution: Living Medicines That Dig In Neobe's approach turns harmless strains of common bacteria into programmable medicines. Once injected, they home in on tumors and release enzymes that dissolve the surrounding matrix—like a key unlocking a door. > "The idea of using bacteria to treat cancer dates back to the early 20th century. But until now, nobody has been able to engineer harmless bacteria to safely home in on tumors and break down these barriers," the company notes. In a 2026 paper in Molecular Cancer Therapeutics, Neobe tested its platform on triple-negative breast cancer that had resisted immunotherapy. A single dose led to complete tumor regression in one model, and when the same cancer was reintroduced months later, no new tumors formed—suggesting lasting immune memory. ### What's Next for Neobe The funding will push Neobe's lead program, NEO22, through preclinical studies toward an IND filing in 2028. The company also appointed Dr. Laura Chow as Chief Medical Officer to oversee clinical development. "We are excited to back Neobe's differentiated approach to overcoming the physical barriers created by dense tumor matrices," says Joseph Korff, founder of Arc Ventures. "Assets derived from Neobe's platform will improve the efficacy of cancer therapies and extend their benefits to more patients." For the European startup ecosystem, Neobe's round is a reminder that deep-tech bio-engineering can attract serious capital—even in a tough funding climate. And if the science holds up, it could change how we think about treating cancer.

đź“Ś Worth Reading Next